FGFR4 and obesity due to melanocortin 4 receptor deficiency: The anti-obesity efficacy of FGFR4 ASO was primarily due to increased basal EE (coupled with decreased lipogenesis), as supported by the following evidence: First, FGFR4 ASO treatment increased whole body O2 consumption and heat production without changing food consumption or locomotor activity.